You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国家医保药品目录调整 14种独家药均降逾43%
阿思达克 12-28 10:12
据《证券时报》报道,国家医疗保障局、人力资源和社会保障部公布《国家基本医疗保险、工伤保险和生育保险药品目录(2020年)》,将於明年3月1日起正式实施。

此次调整共对162种药品进行谈判,119种谈判成功,其中包括96个独家药品,谈判成功率高达73.46%。谈判成功的药品均价降幅过半。

此次调整首次设立目录内药品降价谈判,进一步降低价格或费用偏高、基金占用较多的14种独家药品。这些药品单药的年销售金额均超过10亿元人民币。谈判後,这些药品成功留在目录内,惟均价降43.46%。(ta/w) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account